Document_ID | Conditional | Search Term | CUI | CUI Terms | Similarity Measure |
---|---|---|---|---|---|
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history | C0019664 | History | 1.000 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | physical | C0205485 | Physical | 1.000 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | examination | C4321457 | Examination | 1.000 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | performed | C0884358 | Performed | 1.000 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | patients | C0030705 | Patients | 1.000 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | Heart | C0018787 | Heart | 1.000 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | development | C1527148 | Development | 1.000 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | progression | C0449258 | Progression | 1.000 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | physical examination | C0031809 | Physical Examination | 1.000 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | Heart Failure | C0018801 | Heart failure | 1.000 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | accelerate | C0521110 | Accelerated | 0.947 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | behaviors | C0004927 | Behavior | 0.933 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0150618 | History and physical examination | 0.906 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | obtained | C1301820 | Obtain | 0.833 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | thorough | C0263955 | Thoroughpin | 0.824 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | obtained | C1882120 | Not Obtained | 0.824 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0420160 | History and physical examination, school | 0.814 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0199190 | History and physical examination, limited | 0.800 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0199202 | History and physical examination, license | 0.800 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0199189 | History and physical examination, complete | 0.787 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0199193 | History and physical examination, follow-up | 0.787 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | presenting | C0426109 | Caput presenting | 0.783 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0420111 | History and physical examination, insurance | 0.774 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0199191 | History and physical examination, diagnostic | 0.762 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0199192 | History and physical examination, monitoring | 0.762 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0199198 | History and physical examination, premarital | 0.762 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0481846 | History and physical examination, occupation | 0.762 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0686935 | History and physical examination, immigration | 0.750 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C1293835 | Interview, history AND/OR physical examination | 0.750 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical | C0730554 | History of physical abuse | 0.743 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | examination | C0582103 | Medical Examination | 0.741 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | development | C0243107 | development aspects | 0.741 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | progression | C0242656 | Disease Progression | 0.741 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0686934 | History and physical examination, pre-employment | 0.727 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | presenting | C2735056 | Presenting problem | 0.720 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical examination | C0199197 | History and physical examination, administrative | 0.716 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | examination | C0031809 | Physical Examination | 0.714 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | development | C0678723 | Biologic Development | 0.714 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | Failure | C0018801 | Heart failure | 0.706 |
32470 | A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. | history physical | C1299497 | History and physical report | 0.703 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | patients | C0030705 | Patients | 1.000 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | dilated | C0700124 | Dilated | 1.000 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | family | C0015576 | Family | 1.000 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | history | C0019664 | History | 1.000 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | diagnosis | C0011900 | Diagnosis | 1.000 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | familial | C0241888 | Familial | 1.000 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | family history | C0241889 | Family history | 1.000 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | dilated cardiomyopathy | C0007193 | Cardiomyopathy, Dilated | 0.950 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | cardiomyopathy | C1837350 | No cardiomyopathy | 0.929 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | dilated cardiomyopathy | C3532251 | Fetal dilated cardiomyopathy | 0.889 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | cardiomyopathy | C0878544 | Cardiomyopathies | 0.857 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | obtained | C1301820 | Obtain | 0.833 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | dilated cardiomyopathy | C0340427 | Familial dilated cardiomyopathy | 0.833 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | obtained | C1882120 | Not Obtained | 0.824 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | dilated cardiomyopathy | C0264795 | Secondary dilated cardiomyopathy | 0.816 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | establishing | C2364239 | Establishing Trust | 0.815 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | cardiomyopathy | C0007930 | Chagas Cardiomyopathy | 0.812 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | cardiomyopathy | C0007193 | Cardiomyopathy, Dilated | 0.788 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | establishing | C0443211 | Established | 0.762 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | establishing | C0150735 | Establishing Rapport | 0.759 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | dilated cardiomyopathy | C3668940 | Dmd-Associated Dilated Cardiomyopathy | 0.755 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | idiopathic dilated cardiomyopathy | C1449563 | Cardiomyopathy, Familial Idiopathic | 0.754 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | cardiomyopathy | C0007192 | Cardiomyopathy, Alcoholic | 0.743 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | dilated cardiomyopathy | C0349517 | Dilated cardiomyopathy secondary to drug | 0.727 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | cardiomyopathy | C0007196 | Restrictive cardiomyopathy | 0.703 |
32471 | In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. | dilated cardiomyopathy | C3532231 | Dilated cardiomyopathy with genetic marker | 0.702 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | Volume | C0449468 | Volume | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | status | C0449438 | Status | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | assessed | C1516048 | Assessed | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | encounter | C1947978 | Encounter | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | serial | C4554600 | Serial | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | weight | C0043100 | Weight | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | well | C3146287 | Well | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous | C0348013 | Venous | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | peripheral | C0205100 | Peripheral | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | edema | C0013604 | Edema | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | orthopnea | C0085619 | Orthopnea | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | peripheral edema | C0085649 | Peripheral edema | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | jugular venous pressure | C0428897 | Jugular venous pressure | 1.000 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | patient | C0030705 | Patients | 0.923 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | estimates | C0750572 | Estimated | 0.875 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | pressure | C1882095 | No Pressure | 0.875 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | patient encounter | C0582950 | Patient encounter status | 0.833 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | jugular venous | C0232133 | Jugular venous pulse | 0.828 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | pressure | C0001876 | Air Pressure | 0.824 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous pressure | C0429872 | Venous mean pressure | 0.800 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | patient encounter | C0422288 | Letter encounter to patient | 0.789 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous pressure | C0184275 | Venous pressure monitor | 0.788 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous pressure | C0428640 | Central venous pressure | 0.788 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous pressure | C0428897 | Jugular venous pressure | 0.788 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | includes | C4065484 | diet includes | 0.778 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous pressure | C0042486 | Venous Blood Pressure | 0.774 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous pressure | C0520855 | Venous wedge pressure | 0.774 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | presence | C0150312 | Present | 0.769 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | patient encounter | C0422305 | Patient-initiated encounter | 0.769 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | patient encounter | C0586016 | Patient encounter procedure | 0.769 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous pressure | C0232114 | Abnormal venous pressure | 0.765 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | assessment weight | C1444339 | Weight control assessment | 0.757 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | each | C1882141 | Of Each | 0.750 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | assessment | C0549070 | Assessment: Coping | 0.750 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | vital signs | C0150404 | Taking vital signs | 0.750 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | vital signs | C0277803 | Normal vital signs | 0.750 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | patient encounter | C0422286 | Letter encounter from patient | 0.750 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | jugular venous | C0428897 | Jugular venous pressure | 0.750 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous pressure | C0232115 | Increased venous pressure | 0.743 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous pressure | C0232116 | Decreased venous pressure | 0.743 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | pressure | C0005823 | Blood Pressure | 0.737 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | vital | C0442741 | Non-vital | 0.727 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | venous pressure | C0430477 | Portal venous pressure test | 0.722 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | vital signs | C1290982 | Vital signs finding | 0.720 |
32472 | Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. | weight | C0005910 | Body Weight | 0.714 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | risk | C0035647 | Risk | 1.000 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | useful | C3827682 | Useful | 1.000 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | patients | C0030705 | Patients | 1.000 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | Heart | C0018787 | Heart | 1.000 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | Heart Failure | C0018801 | Heart failure | 1.000 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | estimate | C0750572 | Estimated | 0.933 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | scores | C0449820 | Score | 0.889 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | hospitalized | C0008098 | Child, Hospitalized | 0.815 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | scores | C0871421 | Z-score | 0.800 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | hospitalized | C1546950 | Caused hospitalized | 0.786 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | estimate | C1441495 | Best estimate | 0.778 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | estimate | C1519101 | Risk Estimate | 0.778 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | mortality | C0008083 | Child Mortality | 0.762 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | hospitalized | C0749199 | SYNCOPE HOSPITALIZED | 0.759 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | hospitalized | C0870668 | hospitalized patients | 0.733 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | mortality | C0021278 | Infant Mortality | 0.727 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | subsequent | C4053982 | Subsequent Relapse | 0.720 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | scores | C0237855 | Test scores | 0.714 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | hospitalized | C0747908 | PREGNANCY HOSPITALIZED | 0.710 |
32473 | Validated multivariable risk scores can be useful to estimate subsequent risk of mortality in ambulatory or hospitalized patients with Heart Failure. | Failure | C0018801 | Heart failure | 0.706 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | laboratory | C0022877 | Laboratory | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | evaluation | C0220825 | Evaluation | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | patients | C0030705 | Patients | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | Heart | C0018787 | Heart | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | complete | C0205197 | Complete | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | blood | C0005767 | Blood | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | count | C0750480 | Count | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | urinalysis | C0042014 | Urinalysis | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement | C0242485 | Measurement | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | serum | C0229671 | Serum | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | electrolytes | C0013832 | Electrolytes | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | calcium | C0006675 | Calcium | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | magnesium | C0024467 | Magnesium | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | urea | C0041942 | Urea | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | nitrogen | C0028158 | Nitrogen | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | creatinine | C0010294 | Creatinine | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | glucose | C0017725 | Glucose | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | fasting | C0015663 | Fasting | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | liver | C0023884 | Liver | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | Heart Failure | C0018801 | Heart failure | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | cell count | C0007584 | Cell Count | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | liver function | C0232741 | Liver function | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | blood cell count | C0005771 | Blood Cell Count | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | blood urea nitrogen | C0600137 | Blood Urea Nitrogen | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | fasting lipid profile | C0430044 | Fasting lipid profile | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | liver function tests | C0023901 | Liver Function Tests | 1.000 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum electrolytes | C0587355 | Electrolytes measurement, serum | 0.963 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | blood cell | C0005773 | Blood Cells | 0.941 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | hormone | C0019932 | Hormones | 0.923 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | serum creatinine | C0428282 | Serum creatinine low | 0.903 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | lipid | C0023779 | Lipids | 0.889 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | lipid | C0023767 | Lipid A | 0.889 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | Initial | C0205265 | Initially | 0.857 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | cell | C0007634 | Cells | 0.857 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | serum creatinine | C0600061 | Serum creatinine level | 0.848 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0036792 | Copper measurement, serum | 0.833 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | complete blood | C0009555 | Complete Blood Count | 0.828 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | function tests | C0023901 | Liver Function Tests | 0.828 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0427433 | Serum TIBC measurement | 0.824 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | serum creatinine | C0438244 | Serum creatinine normal | 0.824 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | serum creatinine | C0700225 | Serum creatinine raised | 0.824 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | urea nitrogen | C0600137 | Blood Urea Nitrogen | 0.815 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0202004 | Estriol measurement, serum | 0.811 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0202041 | Glucose measurement, serum | 0.811 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | function tests | C0022662 | Kidney Function Tests | 0.800 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | presenting | C0426109 | Caput presenting | 0.783 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | function | C0700205 | Function Axis | 0.778 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | serum creatinine | C0438243 | Serum creatinine abnormal | 0.778 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | function tests | C0430152 | Gastric function tests | 0.774 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0202020 | Folic acid measurement, serum | 0.769 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0201937 | Carnitine measurement, serum | 0.769 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | calcium magnesium | C0108127 | calcium magnesium phosphate | 0.769 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | calcium magnesium | C2604770 | calcium magnesium carbonate | 0.769 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | blood cell | C0005771 | Blood Cell Count | 0.762 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | fasting lipid | C0430044 | Fasting lipid profile | 0.759 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | lipid profile | C0430044 | Fasting lipid profile | 0.759 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0236281 | Serum lithium measurement | 0.757 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | profile | C0430041 | Bone profile | 0.750 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | magnesium blood | C0580559 | Blood magnesium normal | 0.750 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | function tests | C0430093 | Chemical function tests | 0.750 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | serum electrolytes | C0587355 | Electrolytes measurement, serum | 0.744 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | blood urea nitrogen | C0005845 | Blood urea nitrogen measurement | 0.744 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0236396 | Serum cortisol measurement | 0.737 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | blood urea | C0438241 | Blood urea normal | 0.727 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | function tests | C0024119 | Pulmonary function tests | 0.727 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | presenting | C2735056 | Presenting problem | 0.720 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0202125 | Serum magnesium measurement | 0.718 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0236479 | Serum phenytoin measurement | 0.718 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | measurement serum | C0302353 | Serum potassium measurement | 0.718 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | urea nitrogen | C3683557 | Urea nitrogen (procedure) | 0.710 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | Initial | C1705685 | Initial Usage | 0.706 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | Failure | C0018801 | Heart failure | 0.706 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | profile | C0072073 | profile resin | 0.706 |
32474 | Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. | magnesium blood | C0580560 | Blood magnesium abnormal | 0.706 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | Serial | C4554600 | Serial | 1.000 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | indicated | C1444656 | Indicated | 1.000 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | serum | C0229671 | Serum | 1.000 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | renal function | C0232804 | Renal function | 1.000 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | electrolyte | C0013832 | Electrolytes | 0.952 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | electrolyte | C3536863 | Electrolyte [EPC] | 0.870 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | serum electrolyte levels | C1287347 | Finding of serum electrolyte levels | 0.824 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | electrolyte levels | C0428284 | Electrolyte levels - finding | 0.821 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | electrolyte | C0304459 | Electrolyte agent | 0.800 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | monitoring | C0015945 | Fetal Monitoring | 0.783 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | function | C0700205 | Function Axis | 0.778 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | monitoring | C1283169 | Monitoring - action | 0.750 |
32475 | Serial monitoring, when indicated, should include serum electrolyte levels and renal function. | electrolyte | C0013831 | Electrolyte Balance | 0.741 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | lead | C0023175 | Lead | 1.000 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | electrocardiogram | C0013798 | Electrocardiogram | 1.000 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | performed | C0884358 | Performed | 1.000 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | initially | C0205265 | Initially | 1.000 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | patients | C0030705 | Patients | 1.000 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | Heart | C0018787 | Heart | 1.000 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | Heart Failure | C0018801 | Heart failure | 1.000 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | lead electrocardiogram | C0179504 | Electrocardiogram lead (device) | 0.870 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | lead electrocardiogram | C2960418 | 12 lead electrocardiogram at rest | 0.833 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | lead electrocardiogram | C0199557 | Electrocardiogram, single lead | 0.826 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | presenting | C0426109 | Caput presenting | 0.783 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | lead electrocardiogram | C0199558 | Electrocardiogram, esophageal lead | 0.760 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | presenting | C2735056 | Presenting problem | 0.720 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | lead electrocardiogram | C2960419 | 12 lead electrocardiogram during exercise | 0.714 |
32476 | A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure | Failure | C0018801 | Heart failure | 0.706 |
32477 | Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure. | Screening | C1710032 | Screening | 1.000 |
32477 | Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure. | hemochromatosis | C0018995 | Hemochromatosis | 1.000 |
32477 | Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure. | patients | C0030705 | Patients | 1.000 |
32477 | Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure. | present | C0150312 | Present | 1.000 |
32477 | Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure. | Heart | C0018787 | Heart | 1.000 |
32477 | Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure. | Heart Failure | C0018801 | Heart failure | 1.000 |
32477 | Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure. | Screening hemochromatosis | C1303095 | Hemochromatosis gene screening test | 0.815 |
32477 | Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure. | Failure | C0018801 | Heart failure | 0.706 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | Diagnostic | C0348026 | Diagnostic | 1.000 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | amyloidosis | C0002726 | Amyloidosis | 1.000 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | pheochromocytoma | C0031511 | Pheochromocytoma | 1.000 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | patients | C0030705 | Patients | 1.000 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | Heart | C0018787 | Heart | 1.000 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | clinical | C0205210 | Clinical | 1.000 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | suspicion | C0242114 | Suspicion | 1.000 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | Heart Failure | C0018801 | Heart failure | 1.000 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | diseases | C0012634 | Disease | 0.923 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | presenting | C0426109 | Caput presenting | 0.783 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | diseases | C0003462 | Anus Diseases | 0.778 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | suspicion these | C0242114 | Suspicion | 0.762 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | there clinical | C0205210 | Clinical | 0.737 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | presenting | C2735056 | Presenting problem | 0.720 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | Diagnostic | C0011900 | Diagnosis | 0.706 |
32478 | Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. | Failure | C0018801 | Heart failure | 0.706 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | patients | C0030705 | Patients | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | risk | C0035647 | Risk | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | Heart | C0018787 | Heart | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | natriuretic | C0597421 | natriuretic | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | screening | C1710032 | Screening | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | cardiovascular | C3887460 | Cardiovascular | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | specialist | C1611835 | Specialist | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | useful | C3827682 | Useful | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | development | C1527148 | Development | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left | C0205091 | Left | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular | C1522565 | Ventricular | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | dysfunction | C3887504 | Dysfunction | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | Heart Failure | C0018801 | Heart failure | 1.000 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | dysfunction systolic | C0749225 | Systolic dysfunction | 0.944 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction systolic | C1277187 | Left ventricular systolic dysfunction | 0.939 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | peptide | C0030956 | Peptides | 0.923 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | peptide | C0388060 | peptide A | 0.923 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | peptide | C0006558 | C-Peptide | 0.923 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C3532311 | Fetal left ventricular dysfunction | 0.909 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction | C3532309 | Fetal ventricular dysfunction | 0.894 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction systolic | C3266750 | Mild left ventricular systolic dysfunction | 0.886 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C1997351 | Left ventricular cardiac dysfunction | 0.877 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | followed | C0332283 | Followed by | 0.875 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | natriuretic peptide | C0081880 | Natriuretic Peptide, C-Type | 0.872 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction systolic | C1277187 | Left ventricular systolic dysfunction | 0.871 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction systolic | C3266753 | Severe left ventricular systolic dysfunction | 0.861 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction systolic | C1562095 | Right ventricular systolic dysfunction | 0.857 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C1273070 | Left ventricular diastolic dysfunction | 0.847 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | diastolic | C0442709 | end diastolic | 0.842 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction systolic | C3266752 | Moderate left ventricular systolic dysfunction | 0.838 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C1277187 | Left ventricular systolic dysfunction | 0.828 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | followed | C4697860 | Not Followed | 0.824 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | systolic | C0489485 | end systolic | 0.824 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction | C3532311 | Fetal left ventricular dysfunction | 0.824 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction systolic | C3266750 | Mild left ventricular systolic dysfunction | 0.818 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | cardiovascular | C0007226 | Cardiovascular system | 0.812 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction | C3532310 | Fetal right ventricular dysfunction | 0.808 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | diastolic | C0012000 | Diastole | 0.800 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | dysfunction systolic diastolic | C2711489 | Combined systolic and diastolic dysfunction | 0.800 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction systolic | C1271082 | No evidence of left ventricular systolic dysfunction | 0.795 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction systolic | C3698411 | Asymptomatic left ventricular systolic dysfunction | 0.795 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction systolic | C3266753 | Severe left ventricular systolic dysfunction | 0.794 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction | C1997351 | Left ventricular cardiac dysfunction | 0.792 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | developing | C0227024 | Developing tooth | 0.783 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | followed | C0559897 | Diet followed | 0.778 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | systolic | C0442710 | Peak systolic | 0.778 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular | C0080310 | Left Ventricular Function | 0.778 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C3266750 | Mild left ventricular systolic dysfunction | 0.774 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction systolic | C3266752 | Moderate left ventricular systolic dysfunction | 0.771 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | systolic | C0039155 | Systole | 0.769 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction | C1273070 | Left ventricular diastolic dysfunction | 0.764 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | biomarker | C2349100 | Valid Biomarker | 0.762 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular | C0199646 | Left ventricular recording | 0.757 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular | C0225897 | Left ventricular structure | 0.757 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular | C0232327 | Left ventricular ST changes | 0.757 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular | C0397282 | Left ventricular operation | 0.757 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction systolic | C1319789 | Echocardiogram shows left ventricular systolic dysfunction | 0.753 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction | C1563062 | Right ventricular diastolic dysfunction | 0.750 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C3266753 | Severe left ventricular systolic dysfunction | 0.750 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | development | C0243107 | development aspects | 0.741 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction | C1277187 | Left ventricular systolic dysfunction | 0.741 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction systolic | C2315697 | Chronic systolic dysfunction of left ventricle | 0.740 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | systolic | C0241320 | systolic click | 0.737 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular | C0344906 | Left ventricular hypoplasia | 0.737 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular | C0344911 | Left ventricular dilatation | 0.737 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular | C0397283 | Open left ventricular biopsy | 0.737 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction systolic | C1271082 | No evidence of left ventricular systolic dysfunction | 0.730 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction systolic | C3698411 | Asymptomatic left ventricular systolic dysfunction | 0.730 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | diastolic | C0232276 | Diastolic rumble | 0.727 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction | C1562095 | Right ventricular systolic dysfunction | 0.727 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C3266752 | Moderate left ventricular systolic dysfunction | 0.727 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | ventricular dysfunction systolic | C1532382 | No evidence of right ventricular systolic dysfunction | 0.720 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular | C0149721 | Left Ventricular Hypertrophy | 0.718 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular | C0344905 | Left ventricular abnormality | 0.718 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | development | C0678723 | Biologic Development | 0.714 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C1532126 | Left ventricular dysfunction monitoring invitation | 0.714 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | Failure | C0018801 | Heart failure | 0.706 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C1446272 | No evidence of left ventricular diastolic dysfunction | 0.704 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C1532125 | Left ventricular dysfunction monitoring first letter | 0.704 |
32479 | For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. | left ventricular dysfunction | C1532128 | Left ventricular dysfunction monitoring third letter | 0.704 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | patients | C0030705 | Patients | 1.000 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | dyspnea | C0013404 | Dyspnea | 1.000 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | measurement | C0242485 | Measurement | 1.000 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | natriuretic | C0597421 | natriuretic | 1.000 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | useful | C3827682 | Useful | 1.000 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | diagnosis | C0011900 | Diagnosis | 1.000 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | exclusion | C2828389 | Exclusion | 1.000 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | Heart | C0018787 | Heart | 1.000 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | Heart Failure | C0018801 | Heart failure | 1.000 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | peptide | C0030956 | Peptides | 0.923 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | peptide | C0388060 | peptide A | 0.923 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | peptide | C0006558 | C-Peptide | 0.923 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | diagnosis exclusion | C4518809 | Diagnosis of exclusion | 0.889 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | measurement natriuretic peptide | C1095989 | Brain natriuretic peptide measurement | 0.885 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | natriuretic peptide | C0081880 | Natriuretic Peptide, C-Type | 0.872 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | measurement natriuretic peptide | C1446047 | Plasma B natriuretic peptide measurement | 0.857 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | presenting | C0426109 | Caput presenting | 0.783 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | biomarkers | C0041366 | Biomarkers, Tumor | 0.783 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | measurement natriuretic | C1095989 | Brain natriuretic peptide measurement | 0.741 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | presenting | C2735056 | Presenting problem | 0.720 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | biomarkers | C2735102 | Cardiac biomarkers | 0.720 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | measurement natriuretic | C1446047 | Plasma B natriuretic peptide measurement | 0.714 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | Failure | C0018801 | Heart failure | 0.706 |
32480 | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | measurement natriuretic | C0201900 | Atrial natriuretic factor (ANF) measurement | 0.702 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | Measurement | C0242485 | Measurement | 1.000 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | useful | C3827682 | Useful | 1.000 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | disease | C0012634 | Disease | 1.000 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | chronic | C0205191 | chronic | 1.000 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | Heart | C0018787 | Heart | 1.000 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | Heart Failure | C0018801 | Heart failure | 1.000 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | chronic Heart Failure | C0264716 | Chronic heart failure | 1.000 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | prognosis | C0278252 | Prognosis bad | 0.842 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | establishing | C2364239 | Establishing Trust | 0.815 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | prognosis | C0278250 | Prognosis good | 0.800 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | prognosis | C0278251 | Fair prognosis | 0.800 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | establishing | C0443211 | Established | 0.762 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | establishing | C0150735 | Establishing Rapport | 0.759 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | chronic Heart | C0264716 | Chronic heart failure | 0.759 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | chronic Heart | C1290386 | Chronic heart disease | 0.759 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | severity | C0439793 | Severities | 0.750 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | severity | C0457451 | Severity score | 0.737 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | prognosis | C0548855 | fear of prognosis | 0.727 |
32481 | Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. | Failure | C0018801 | Heart failure | 0.706 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | Measurement | C0242485 | Measurement | 1.000 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | baseline | C1442488 | Baseline | 1.000 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | natriuretic | C0597421 | natriuretic | 1.000 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | troponin | C0041199 | Troponin | 1.000 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | useful | C3827682 | Useful | 1.000 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | decompensated | C0205434 | Decompensated | 1.000 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | Heart | C0018787 | Heart | 1.000 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | Heart Failure | C0018801 | Heart failure | 1.000 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | cardiac troponin | C1305957 | Cardiac troponin I | 0.966 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | admission hospital | C0184666 | Hospital admission | 0.938 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | hospital | C0019994 | Hospitals | 0.933 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | peptide | C0030956 | Peptides | 0.923 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | peptide | C0388060 | peptide A | 0.923 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | peptide | C0006558 | C-Peptide | 0.923 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | admission | C0457453 | On admission | 0.889 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | admission | C4533677 | at admission | 0.889 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | establish | C0443211 | Established | 0.889 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | hospital | C4035588 | Hospital-OR | 0.875 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | natriuretic peptide | C0081880 | Natriuretic Peptide, C-Type | 0.872 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | admission | C0559269 | Pre-admission | 0.842 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | prognosis | C0278252 | Prognosis bad | 0.842 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | decompensated Heart Failure | C1827266 | Decompensated chronic heart failure | 0.836 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | establish | C0677368 | Establish fees | 0.800 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | prognosis | C0278250 | Prognosis good | 0.800 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | prognosis | C0278251 | Fair prognosis | 0.800 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | biomarkers | C0041366 | Biomarkers, Tumor | 0.783 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | admission hospital | C0184680 | Hospital admission, special | 0.769 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | establish | C0511063 | Establish goals | 0.762 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | admission hospital | C0184667 | Hospital admission, elective | 0.750 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | cardiac troponin | C3538889 | Troponin T, Cardiac Muscle | 0.743 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | admission hospital | C0184673 | Emergency hospital admission | 0.732 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | prognosis | C0548855 | fear of prognosis | 0.727 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | biomarkers | C2735102 | Cardiac biomarkers | 0.720 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | admission hospital | C0184694 | Hospital admission, blood donor | 0.714 |
32482 | Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. | Failure | C0018801 | Heart failure | 0.706 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | During | C0347984 | During | 1.000 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | Heart | C0018787 | Heart | 1.000 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | hospitalization | C0019993 | Hospitalization | 1.000 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | natriuretic | C0597421 | natriuretic | 1.000 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | level | C2946261 | Level | 1.000 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | useful | C3827682 | Useful | 1.000 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | Heart Failure | C0018801 | Heart failure | 1.000 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | peptide | C0030956 | Peptides | 0.923 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | peptide | C0388060 | peptide A | 0.923 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | peptide | C0006558 | C-Peptide | 0.923 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | establish | C0443211 | Established | 0.889 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | natriuretic peptide | C0081880 | Natriuretic Peptide, C-Type | 0.872 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | prognosis | C0278252 | Prognosis bad | 0.842 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | establish | C0677368 | Establish fees | 0.800 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | prognosis | C0278250 | Prognosis good | 0.800 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | prognosis | C0278251 | Fair prognosis | 0.800 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | natriuretic peptide level | C1319570 | Serum pro-brain natriuretic peptide level | 0.772 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | establish | C0511063 | Establish goals | 0.762 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | natriuretic peptide level | C1318675 | Plasma pro-brain natriuretic peptide level | 0.759 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | prognosis | C0548855 | fear of prognosis | 0.727 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | natriuretic peptide level | C1533071 | N terminal pro-brain natriuretic peptide level | 0.721 |
32483 | During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. | Failure | C0018801 | Heart failure | 0.706 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | patients | C0030705 | Patients | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | chronic | C0205191 | chronic | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | Heart | C0018787 | Heart | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | measurement | C0242485 | Measurement | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | other | C0205394 | Other | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | myocardial | C1522564 | Myocardial | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | fibrosis | C0016059 | Fibrosis | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | additive | C0442796 | Additive | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | risk | C0035647 | Risk | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | stratification | C1514983 | Stratification | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | Heart Failure | C0018801 | Heart failure | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | chronic Heart Failure | C0264716 | Chronic heart failure | 1.000 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | considered | C0750591 | consider | 0.875 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | available | C1511733 | Date Available | 0.800 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | biomarkers | C0041366 | Biomarkers, Tumor | 0.783 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | myocardial | C0027061 | Myocardium | 0.778 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | chronic Heart | C0264716 | Chronic heart failure | 0.759 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | chronic Heart | C1290386 | Chronic heart disease | 0.759 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | considered | C3840836 | Considered futile | 0.750 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | available | C0557465 | No help available | 0.727 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | clinically | C0856661 | Clinically shocked | 0.720 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | biomarkers | C2735102 | Cardiac biomarkers | 0.720 |
32484 | In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. | Failure | C0018801 | Heart failure | 0.706 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | Patients | C0030705 | Patients | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | Heart | C0018787 | Heart | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | acute | C0205178 | acute | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | decompensated | C0205434 | Decompensated | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | chest | C0817096 | Chest | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | size | C0456389 | size | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | congestion | C0700148 | Congestion | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | alternative | C1523987 | Alternative | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | other | C0205394 | Other | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | symptoms | C1457887 | Symptoms | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | Heart Failure | C0018801 | Heart failure | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | pulmonary congestion | C0242073 | Pulmonary congestion | 1.000 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | diseases | C0012634 | Disease | 0.923 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | patient | C0030705 | Patients | 0.923 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | suspected | C1997218 | NOT suspected | 0.842 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | decompensated Heart Failure | C1827266 | Decompensated chronic heart failure | 0.836 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | assess | C1516048 | Assessed | 0.833 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | detect | C1330713 | EZ Detect | 0.833 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | contribute | C1880177 | Contribution | 0.800 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | presenting | C0426109 | Caput presenting | 0.783 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | diseases | C0003462 | Anus Diseases | 0.778 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | cardiac pulmonary | C0398350 | Acute cardiac pulmonary edema | 0.750 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | presenting | C2735056 | Presenting problem | 0.720 |
32485 | Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. | Failure | C0018801 | Heart failure | 0.706 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | performed | C0884358 | Performed | 1.000 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | during | C0347984 | During | 1.000 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | evaluation | C0220825 | Evaluation | 1.000 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | patients | C0030705 | Patients | 1.000 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | Heart | C0018787 | Heart | 1.000 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | ventricular | C1522565 | Ventricular | 1.000 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | size | C0456389 | size | 1.000 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | motion | C0026597 | Motion | 1.000 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | Heart Failure | C0018801 | Heart failure | 1.000 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | dimensional | C1705052 | 2-Dimensional | 0.952 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | ventricular function | C0080310 | Left Ventricular Function | 0.900 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | ventricular function | C0080311 | Ventricular Function, Right | 0.878 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | echocardiogram | C0013516 | Echocardiography | 0.857 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | initial | C0205265 | Initially | 0.857 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | echocardiogram | C2243117 | Echocardiogram (image) | 0.839 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | assess | C1516048 | Assessed | 0.833 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | valve function | C0588136 | Heart valve function | 0.828 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | echocardiogram | C0436484 | Echocardiogram normal | 0.812 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | echocardiogram | C0743380 | echocardiogram result | 0.812 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | dimensional | C0450363 | Three-dimensional | 0.800 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | valve function | C0428789 | Aortic valve function | 0.800 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | valve function | C0428799 | Mitral valve function | 0.800 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | presenting | C0426109 | Caput presenting | 0.783 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | function | C0700205 | Function Axis | 0.778 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | ventricular function | C1287715 | Left ventricular function - finding | 0.766 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | echocardiogram | C0476369 | Echocardiogram abnormal | 0.765 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | echocardiogram | C1319340 | Echocardiogram declined | 0.765 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | ventricular function | C0553982 | Impaired left ventricular function | 0.750 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | ventricular function | C1287720 | Right ventricular function - finding | 0.750 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | echocardiogram | C1303038 | Echocardiogram requested | 0.743 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | thickness | C0239600 | FINGER THICKNESS | 0.727 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | thickness | C0332524 | Normal thickness | 0.727 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | thickness | C0423756 | Thickness of skin | 0.727 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | valve function | C0428814 | Pulmonary valve function | 0.727 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | valve function | C0428815 | Tricuspid valve function | 0.727 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | presenting | C2735056 | Presenting problem | 0.720 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | wall motion | C0232167 | Cardiac wall motion | 0.720 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | echocardiogram | C0920208 | Echocardiography, Stress | 0.706 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | Doppler | C0430489 | Laser doppler | 0.706 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | initial | C1705685 | Initial Usage | 0.706 |
32486 | A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. | Failure | C0018801 | Heart failure | 0.706 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | Repeat | C0205341 | Repeat | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | measurement | C0242485 | Measurement | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | useful | C3827682 | Useful | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | information | C1533716 | Information | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | patients | C0030705 | Patients | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | Heart | C0018787 | Heart | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | significant | C0750502 | Significant | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | clinical | C0205210 | Clinical | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | status | C0449438 | Status | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | event | C0441471 | Event | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | effect | C1280500 | Effect | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | Heart Failure | C0018801 | Heart failure | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | clinical status | C0449440 | Clinical status | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | cardiac function | C0232164 | Cardiac function | 1.000 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | received | C1514756 | Receive | 0.923 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | device | C0699733 | Devices | 0.909 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | treatment | C0746919 | NO TREATMENT | 0.889 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | received | C1709850 | Received By | 0.875 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | structural | C0678594 | structure | 0.824 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | received | C0729795 | Fax received | 0.824 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | structural | C0017366 | Structural gene | 0.818 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | remodeling | C0085268 | Bone remodeling | 0.818 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | therapy | C0003827 | Art Therapy | 0.800 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | received | C1115441 | Date received | 0.778 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | function | C0700205 | Function Axis | 0.778 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | recovered | C1546957 | Fully recovered | 0.762 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | treatment | C3161471 | Treatment Study | 0.762 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | treatment | C3538994 | Treatment Epoch | 0.762 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | severity | C0439793 | Severities | 0.750 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | structural | C0026349 | Models, Structural | 0.750 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | remodeling | C1820201 | tissue remodeling | 0.750 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | provide | C0593738 | Provide Xtra | 0.750 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | therapy | C0010412 | Cold Therapy | 0.750 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | severity | C0457451 | Severity score | 0.737 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | candidates | C1549320 | QBP _ Find candidates | 0.720 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | device therapy | C3880777 | Dry salt therapy device | 0.710 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | device therapy | C3881193 | Cupping therapy device | 0.710 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | Failure | C0018801 | Heart failure | 0.706 |
32487 | Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. | therapy | C0010962 | Dance Therapy | 0.706 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | Noninvasive | C2986496 | Noninvasive | 1.000 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | myocardial | C1522564 | Myocardial | 1.000 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | ischemia | C0022116 | Ischemia | 1.000 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | patients | C0030705 | Patients | 1.000 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | Heart | C0018787 | Heart | 1.000 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | known | C0205309 | Known | 1.000 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | eligible | C1548635 | Eligible | 1.000 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | myocardial ischemia | C0151744 | Myocardial Ischemia | 1.000 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | Heart Failure | C0018801 | Heart failure | 1.000 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | patient | C0030705 | Patients | 0.923 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | revascularization | C0472662 | Limb revascularization | 0.889 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | revascularization | C0581603 | Revascularization - action | 0.842 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | revascularization | C0472666 | Revascularization of hand | 0.842 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | revascularization | C0472672 | Revascularization of foot | 0.842 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | detect | C1330713 | EZ Detect | 0.833 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | revascularization | C0472667 | Revascularization of thumb | 0.821 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | revascularization | C0007794 | Cerebral Revascularization | 0.800 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | revascularization | C0472668 | Revascularization of finger | 0.800 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | presenting | C0426109 | Caput presenting | 0.783 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | revascularization | C0472665 | Revascularization of forearm | 0.780 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | myocardial | C0027061 | Myocardium | 0.778 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | viability | C0015954 | Fetal Viability | 0.762 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | viability | C0449583 | Viability of gut | 0.762 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | viability | C1300991 | Tumor viability | 0.762 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | viability | C1442040 | Viability count | 0.762 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | revascularization | C0027056 | Myocardial Revascularization | 0.762 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | viability | C1449935 | Tissue Viability | 0.727 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | revascularization | C0472582 | Revascularization for impotence | 0.727 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | presenting | C2735056 | Presenting problem | 0.720 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | angina | C0019338 | Herpangina | 0.714 |
32488 | Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. | Failure | C0018801 | Heart failure | 0.706 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | Heart | C0018787 | Heart | 1.000 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | patients | C0030705 | Patients | 1.000 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | Heart Failure | C0018801 | Heart failure | 1.000 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization | C0472662 | Limb revascularization | 0.889 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization | C0581603 | Revascularization - action | 0.842 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization | C0472666 | Revascularization of hand | 0.842 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization | C0472672 | Revascularization of foot | 0.842 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | select | C1651012 | Select-OB | 0.833 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization | C0472667 | Revascularization of thumb | 0.821 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization | C0007794 | Cerebral Revascularization | 0.800 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization | C0472668 | Revascularization of finger | 0.800 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization Heart | C0189976 | Indirect heart revascularization | 0.800 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization | C0472665 | Revascularization of forearm | 0.780 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | planning | C0008866 | City Planning | 0.778 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | select | C2730299 | PNV Select | 0.769 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | Viability | C0015954 | Fetal Viability | 0.762 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | Viability | C0449583 | Viability of gut | 0.762 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | Viability | C1300991 | Tumor viability | 0.762 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | Viability | C1442040 | Viability count | 0.762 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization | C0027056 | Myocardial Revascularization | 0.762 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | assessment | C0549070 | Assessment: Coping | 0.750 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | Viability | C1449935 | Tissue Viability | 0.727 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization | C0472582 | Revascularization for impotence | 0.727 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization Heart | C0190058 | Grafting of heart for revascularization | 0.727 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | revascularization Heart | C0027056 | Myocardial Revascularization | 0.723 |
32489 | Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. | Failure | C0018801 | Heart failure | 0.706 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | useful | C3827682 | Useful | 1.000 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | volume | C0449468 | Volume | 1.000 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | echocardiography | C0013516 | Echocardiography | 1.000 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | Radionuclide ventriculography | C0034610 | Radionuclide Ventriculography | 1.000 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | magnetic resonance imaging | C0024485 | Magnetic Resonance Imaging | 1.000 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | ventriculography | C0846023 | Right ventriculography | 0.857 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | assess | C1516048 | Assessed | 0.833 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | magnetic resonance | C0024485 | Magnetic Resonance Imaging | 0.821 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | ventriculography | C0596683 | Cardiac ventriculography | 0.811 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | magnetic | C0563532 | Magnetism | 0.800 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | ventriculography | C0007800 | Cerebral Ventriculography | 0.789 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | resonance imaging | C0024485 | Magnetic Resonance Imaging | 0.789 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | magnetic | C0427170 | Magnetic gait | 0.778 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | magnetic | C0681512 | magnetic tape | 0.778 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | ventriculography | C0042516 | Ventriculography, First-Pass | 0.769 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | resonance | C0314720 | Vocal resonance | 0.762 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | Radionuclide | C0034606 | Radionuclide Imaging | 0.759 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | ventriculography | C0412219 | Left ventriculogram | 0.750 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | magnetic resonance | C0243032 | Magnetic Resonance Angiography | 0.744 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | magnetic resonance | C0336660 | Magnetic resonance imaging unit | 0.744 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | magnetic | C0439876 | Magnetic metal | 0.737 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | magnetic resonance | C0024487 | Magnetic Resonance Spectroscopy | 0.727 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | ventriculography | C0034610 | Radionuclide Ventriculography | 0.714 |
32490 | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | resonance imaging | C0336660 | Magnetic resonance imaging unit | 0.714 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | myocardial | C1522564 | Myocardial | 1.000 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | burden | C2828008 | Burden | 1.000 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | Magnetic resonance imaging | C0024485 | Magnetic Resonance Imaging | 1.000 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | Magnetic resonance | C0024485 | Magnetic Resonance Imaging | 0.821 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | Magnetic | C0563532 | Magnetism | 0.800 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | resonance imaging | C0024485 | Magnetic Resonance Imaging | 0.789 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | Magnetic | C0427170 | Magnetic gait | 0.778 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | Magnetic | C0681512 | magnetic tape | 0.778 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | myocardial | C0027061 | Myocardium | 0.778 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | resonance | C0314720 | Vocal resonance | 0.762 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | processes | C0018265 | Group Processes | 0.762 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | Magnetic resonance | C0243032 | Magnetic Resonance Angiography | 0.744 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | Magnetic resonance | C0336660 | Magnetic resonance imaging unit | 0.744 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | Magnetic | C0439876 | Magnetic metal | 0.737 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | infiltrative | C1168158 | Infiltrative erythema | 0.733 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | assessing | C0548299 | Assessing Oedema | 0.727 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | assessing | C1999048 | Assessing Coping | 0.727 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | assessing | C2364225 | Assessing Denial | 0.727 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | processes | C0025361 | Mental Processes | 0.727 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | Magnetic resonance | C0024487 | Magnetic Resonance Spectroscopy | 0.727 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | resonance imaging | C0336660 | Magnetic resonance imaging unit | 0.714 |
32491 | Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. | infiltrative | C3842356 | Diffusely infiltrative | 0.710 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | Routine | C0205547 | Routine | 1.000 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | repeat | C0205341 | Repeat | 1.000 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | measurement | C0242485 | Measurement | 1.000 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | clinical | C0205210 | Clinical | 1.000 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | status | C0449438 | Status | 1.000 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | performed | C0884358 | Performed | 1.000 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | clinical status | C0449440 | Clinical status | 1.000 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | status change | C0442739 | No status change | 0.917 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | treatment | C0746919 | NO TREATMENT | 0.889 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | function assessment | C2732244 | School function assessment | 0.850 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | measurement function | C2711919 | Measurement of renal function | 0.791 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | function | C0700205 | Function Axis | 0.778 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | interventions | C0886296 | Nursing interventions | 0.774 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | treatment | C3161471 | Treatment Study | 0.762 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | treatment | C3538994 | Treatment Epoch | 0.762 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | interventions | C0010332 | Crisis Intervention | 0.759 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | change treatment | C0419902 | Endocrine treatment change | 0.757 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | function assessment | C2959524 | School function assessment score | 0.756 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | assessment | C0549070 | Assessment: Coping | 0.750 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | interventions | C1273869 | Intervention regimes | 0.733 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | absence | C0332197 | Absent | 0.727 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | function assessment | C4518444 | Assessment of fine motor function | 0.711 |
32492 | Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. | interventions | C3542921 | CDISC Interventions Class | 0.706 |
32493 | Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment. | Invasive | C0205281 | Invasive | 1.000 |
32493 | Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment. | performed | C0884358 | Performed | 1.000 |
32493 | Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment. | patients | C0030705 | Patients | 1.000 |
32493 | Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment. | respiratory | C0521346 | respiratory | 1.000 |
32493 | Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment. | distress | C0231303 | Distress | 1.000 |
32493 | Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment. | clinical | C0205210 | Clinical | 1.000 |
32493 |